Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) Director Elaine Heron purchased 2,400 shares of Palvella Therapeutics stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of $125.00 per share, with a total value of $300,000.00. Following the acquisition, the director directly owned 47,812 shares of the company's stock, valued at $5,976,500. The trade was a 5.28% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
Palvella Therapeutics Trading Down 1.8%
PVLA stock opened at $132.61 on Tuesday. Palvella Therapeutics, Inc. has a twelve month low of $18.23 and a twelve month high of $151.18. The company has a market capitalization of $1.57 billion, a P/E ratio of -50.42 and a beta of -0.31. The firm has a 50 day simple moving average of $95.00 and a 200-day simple moving average of $81.11.
Hedge Funds Weigh In On Palvella Therapeutics
Hedge funds and other institutional investors have recently modified their holdings of the company. Group One Trading LLC grew its position in shares of Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company's stock worth $35,000 after acquiring an additional 200 shares during the last quarter. Archer Investment Corp bought a new stake in Palvella Therapeutics in the 3rd quarter valued at about $28,000. Russell Investments Group Ltd. acquired a new position in Palvella Therapeutics during the 3rd quarter valued at about $36,000. China Universal Asset Management Co. Ltd. bought a new position in Palvella Therapeutics in the 4th quarter worth about $167,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Palvella Therapeutics in the second quarter valued at approximately $37,000. Institutional investors and hedge funds own 40.11% of the company's stock.
Analysts Set New Price Targets
Several research analysts have recently commented on PVLA shares. Raymond James Financial reiterated a "strong-buy" rating and issued a $193.00 target price on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. TD Cowen reaffirmed a "buy" rating on shares of Palvella Therapeutics in a report on Monday, February 2nd. Oppenheimer reissued an "outperform" rating and set a $200.00 target price on shares of Palvella Therapeutics in a report on Monday, December 15th. BTIG Research raised their price target on shares of Palvella Therapeutics from $192.00 to $215.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Finally, Stifel Nicolaus set a $250.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $176.44.
View Our Latest Stock Analysis on Palvella Therapeutics
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.
Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
